in2cure has raised SEK 10 million in venture capital from private investors. The company, a member of SmiLe Incubator in Lund, is developing a gel to promote wound healing based on research at Lund University. in2cure is now accelerating development and plans to initiate clinical studies at the end of 2019. Helene Hartman, previously a member of the board of directors, is taking over as the new CEO.
in2cure was founded by Dr. Artur Schmidtchen, Professor of Dermatology and Venereology at Lund University and a physician at Skåne University Hospital. He has analyzed how endogenous peptides act to fight infection, reduce inflammation and deactivate the toxic substances that form when the bacteria enter the body. The trailblazing research findings were recently published in the prestigious journal Nature Communication.
These discoveries could lead to a completely new type of modern medication, which unlike antibiotics, has a more natural and flexible mode of action and therefore does not create resistance.
“In a future when we can no longer use antibiotics in the same way as today, we must find alternative modalities to protect ourselves and to prevent infection. At in2cure we are now developing a treatment to promote wound healing based on this natural defense, and the infusion of capital will enable us to accelerate the development of our drug candidate BioC. We plan to initiate clinical trials in about one year. The discovery will form a platform that the company can subsequently develop for additional indications,” says Helene Hartman, CEO of in2cure.
Helene Hartman has worked on the company’s board of directors since 2014 and is now assuming the position of CEO. She has extensive experience of strategic development at Tetra Pak and from working on other boards of directors.
Earlier this year in2cure received SEK 200,000 from the Sten K Johnson Foundation, as well as a grant from Novo Seeds in Denmark.
in2cure is a startup company in SmiLe Incubator, which supports life science entrepreneurs with business development and access to well-equipped laboratories, and is located at Medicon Village in Lund.
About in2cure: in2cure develops medications based on BioC, an endogenous peptide. As part of the body's immune system, BioC has been carefully analyzed, revealing that it suppresses inflammation, prevents infection and neutralizes endotoxins. BioCure is a platform for the development of modern medications for the post-antibiotics era. As a first application, in2cure is developing a wound treatment gel, with plans to initiate clinical studies in late 2019.